Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Interim efficacy, updated safety analyses from Phase III breast cancer study presented
January 19th, 2006
The Breast Cancer International Research Group (BCIRG) and the sanofi-aventis announced the results from the first interim efficacy and updated safety analyses from the BCIRG 006 phase III breast cancer study, which show that Herceptin combined with Taxotere-based regimens significantly improved disease free survival for women with early HER2-positive breast cancer. This data was presented at the 28th annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. Cardiac and global safety data together with the interim efficacy analysis based on 322 events were reviewed by an Independent Data Monitoring Committee (IDMC). The relative...
Source: Women's Health Weekly (2006-01-19)
|
